Ionis Pharmaceuticals (IONS) Long-Term Deferred Tax (2012 - 2020)

Ionis Pharmaceuticals' Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $307.7 million for Q3 2020.

• On a quarterly basis, Long-Term Deferred Tax rose 7.98% year-over-year to $307.7 million in Q3 2020; TTM through Sep 2020 was $307.7 million, a 7.98% increase from a year earlier, with the FY2019 full-year figure at $305.6 million, up 5.08% from the prior year.
• Long-Term Deferred Tax improved to $307.7 million in Q3 2020 per IONS's latest filing, from $306.0 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $309.6 million in Q1 2020 and bottomed at $276.4 million in Q2 2019.
• The 3-year median for Long-Term Deferred Tax is $298.2 million (2018), against an average of $294.8 million.
• Across the five-year window, Long-Term Deferred Tax rose 5.08% in 2019 and increased 11.67% in 2020, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $290.8 million in 2018, then gained by 5.08% to $305.6 million in 2019, then rose by 0.71% to $307.7 million in 2020.
• Per Business Quant, the three latest IONS Long-Term Deferred Tax figures stand at $307.7 million (Q3 2020), $306.0 million (Q2 2020), and $309.6 million (Q1 2020).